2026-06-14T03:55:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/168352024-11-28T17:54:12Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16961

00925njm 22002777a 4500 dc Rodríguez-Agustín, Andrea author Casanova, Víctor author Grau-Expósito, Judith author Sánchez-Palomino, Sonsoles author Alcamí, José author Climent, Núria author 2023-03-11 Tyrosine kinase inhibitors (TKIs) have been extensively used as a treatment for chronic myeloid leukemia (CML). Dasatinib is a broad-spectrum TKI with off-target effects that give it an immunomodulatory capacity resulting in increased innate immune responses against cancerous cells and viral infected cells. Several studies reported that dasatinib expanded memory-like natural killer (NK) cells and γδ T cells that have been related with increased control of CML after treatment withdrawal. In the HIV infection setting, these innate cells are associated with virus control and protection, suggesting that dasatinib could have a potential role in improving both the CML and HIV outcomes. Moreover, dasatinib could also directly induce apoptosis of senescence cells, being a new potential senolytic drug. Here, we review in depth the current knowledge of virological and immunogenetic factors associated with the development of powerful cytotoxic responses associated with this drug. Besides, we will discuss the potential therapeutic role against CML, HIV infection and aging. Pharmaceutics. 2023 Mar 11;15(3):917. 10.3390/pharmaceutics15030917 1999-4923 Pharmaceutics 36986778 http://hdl.handle.net/20.500.12105/16835 Dasatinib Tyrosine kinase inhibitors CML Cancer HIV-1 CMV HIV functional cure Memory-like NK cells γδ T cells Anti-aging Senolytic Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging